|
|
 |
Neulasta® safety information |
| |
|
|
|
|
Adverse events occurring in ≥ 10%a of patients9
|
|
|
|
| Event |
| Alopecia |
48% |
47% |
| Bone painb |
31% |
26% |
| Diarrhea |
29% |
28% |
Pyrexia
(not including febrile neutropenia) |
23% |
22% |
| Myalgia |
21% |
18% |
| Headache |
16% |
14% |
| Arthralgia |
16% |
13% |
| Vomiting |
13% |
11% |
| Asthenia |
13% |
11% |
| Peripheral edema |
12% |
10% |
| Constipation |
10% |
6% |
|
|
|
|
|
aEvents occurring in ≥ 10% of Neulasta®-treated patients and at a higher incidence as compared to placebo-treated patients.
bBone pain is limited to the specified adverse event term, "bone pain."
|
|
|
| |
Based on a composite analysis using multiple, related adverse event terms to describe
bone pain resulted in incidence of mild-to-moderate bone pain of 57% vs 50% in
Neulasta®-treated patients and in placebo-treated patients respectively. |
 |
|
